Scipher Medicine

Executive Summary

Scipher Medicine is a precision immunology company leveraging its proprietary artificial intelligence platform to match patients with autoimmune diseases to their most effective therapies. Founded in 2015 and based in Waltham, Massachusetts, the company analyzes patients' molecular data to guide therapy selection and accelerate drug development. Its core offering, PrismRA, is a blood test that predicts which rheumatoid arthritis patients will respond to TNF-alpha inhibitors, enabling cost savings and better outcomes. By focusing on the high-need autoimmune market, Scipher aims to reduce trial-and-error prescribing and improve patient quality of life. Scipher has demonstrated clinical utility through studies validating its test's ability to reduce healthcare costs and improve treatment response rates. The company has forged partnerships with biopharmaceutical firms to expand its molecular testing into other autoimmune indications. With a growing emphasis on personalized medicine, Scipher is well-positioned to capture a significant share of the companion diagnostics market. Its data-driven approach and strong intellectual property portfolio provide a competitive edge. As the company scales commercially and pushes for regulatory clearances, it stands to benefit from the broader shift toward precision medicine in immunology.

Upcoming Catalysts (preview)

• Q1 2027FDA 510(k) clearance or expanded indication for PrismRA test75% success
• Q2 2027Strategic partnership with a top-20 pharmaceutical company for companion diagnostic development60% success
• Q3 2026Publication of pivotal clinical validation data in a peer-reviewed journal for a second autoimmune indication80% success